| Alias |
XL184;Cabozantinib (XL184, BMS-907351);1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-;1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;C28H24FN3O5;Cabozantinib;Cabozantinib (XL184,BMS 907351,Cometriq®);Cabozantinib S-malate;Cabozantinib, XL184;N-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;XL-180;XL-184;XL184 Cabozantinib;[14C]-Cabozantinib;BMS907351;BMS-907351;Cometriq;cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide;N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;Cabozantinib Impurity;1,1-Cyclopropanedicarboxamide, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N′-(4-fluorophenyl)- (9CI);N′-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (ACI);1-N-[4-(6,7-Dimethoxyquinolin-4-yl)oxyphenyl]-1-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;BMS 907351;Cabometyx;XL 184;Cabozantinib (USAN);Cabozantinib (USAN);Cabozantinib (USAN);Cabozantinib (USAN);XL184 cpd;XL184 cpd;XL184 cpd;XL184 cpd;UNII-1C39JW444G;UNII-1C39JW444G;UNII-1C39JW444G;UNII-1C39JW444G;CABOZANTINIB [INN];CABOZANTINIB [INN];CABOZANTINIB [INN];CABOZANTINIB [INN];CABOZANTINIB [WHO-DD];CABOZANTINIB [WHO-DD];CABOZANTINIB [WHO-DD];CABOZANTINIB [WHO-DD];NSC-800066;NSC-800066;NSC-800066;NSC-800066;HMS3654G06;HMS3654G06;HMS3654G06;HMS3654G06;BCP9000470;BCP9000470;BCP9000470;BCP9000470;D10062;D10062;D10062;D10062;EX-A075;EX-A075;EX-A075;EX-A075;N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE;N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE;N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE;N'-[4-[(6,7-DIMETHOXY-4-QUINOLINYL)OXY]PHENYL]-N-(4-FLUOROPHENYL)-1,1-CYCLOPROPANEDICARBOXAMIDE;BDBM50021574;BDBM50021574;BDBM50021574;BDBM50021574;NCGC00263164-17;NCGC00263164-17;NCGC00263164-17;NCGC00263164-17;Q795057;Q795057;Q795057;Q795057;N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;N1-[4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-N1'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;XL-184 free base;XL-184 free base;XL-184 free base;XL-184 free base;Cabozantinib (BMS-907351);Cabozantinib (BMS-907351);Cabozantinib (BMS-907351);Caboz... |
